Natera
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial
Investigators are using the Signatera ctDNA test to guide treatment decisions for high-risk colon cancer patients based on their tumor genetics.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
Natera Signatera MRD Test to Guide, Assess Treatment in Phase II Gastroesophageal Cancer Study
The Signatera ctDNA test will be used to evaluate the efficacy of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in the Phase II DECIPHER trial.
As ctDNA testing for early-stage tumors gains traction, clinicians eagerly await more clarity on overall utility and the potential value of increased sensitivity.